Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study ID
NCT02272790

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

Trial Summary

Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.

More informations

Trial Starting Date

Jan 30,2015

Requirements

Gender Female
Minimum age 18 Years
Maximum age 130 Years

Enrollement Limit